available only through 503A compounding pharmacies under physician supervision Typical research dose range / 200-800 mcg/day subcutaneously, cycled 4-8 weeks Known lethal dose (LD50) / Not established in any species studied to date Rodent acute toxicity ceiling / No mortality observed at doses exceeding 10 mg/kg intraperitoneally Most reported excess-dose symptoms / Nausea, lightheadedness, flushing, injection-site irritation Organ toxicity at supratherapeutic doses / Not demonstrated in published preclinical literature Antidote availability / No specific antidote exists
In addition to being associated with excellent health and longevity, glutathione has been demonstrated to decrease visible signs of aging, such as reducing wrinkling and increasing skin elasticity
The balance and coordination issues that severe deficiency can cause raise the risk of falls, which is a focus of our geriatric care
These resources explain documentation and analytical verification only
At four weeks, the melanin indices decreased consistently at all six sites in the glutathione group
Results from a Phase III trial met the criteria for non-inferiority and superiority compared to piperacillin/tazobactam in the primary outcome of clinical cure and microbiological eradication in patients with complicated UTIs
